抗衰老药物的研究进展

何晨1，刘晶晶1，陈楠1，段路娟1，王斓星1，王丽丽2+(1．河北农业大学生命科学学院，保定071000；2．河北农业大学中国枣研究中心，保定071000)

摘要：目的

总结近年来研究人员在抗衰老药物研究领域的发现，为后期研究提供参考。方法通过查阅近5年的相关文献，对抗衰老药物进行分类归纳。结果抗衰老药物大致可分为中药类(如当归、人参和蜂王浆等)、小分子类(如二甲双胍、白藜芦醇、原花青素和雷帕霉素)和多肽类(如大米多肽、大豆多肽和人工合成多肽)，通过构建不同的生物模型(如D半乳糖致衰老小鼠模型、p53基因敲除斑马鱼模型和秀丽隐杆线虫模型等)可证实其抗衰老作用。结论尽管抗衰老药物的作用效果得到了证实，但其分子作用机制有待进一步阐明。

关键词：抗衰老药物；中药类；小分子类；多肽类

DOI：10．3969／i．issn．1004—2407．2020．01．035

中图分类号：R977

文献标志码：A

文章编号：1004—2407(2020)01一0154一04

点阵二氧化碳激光对眶周皮肤年轻化有效性、 安全性和满意度的系统综述及荟萃分析

袁 悦1 ，纪晓晖1 ，顾敬喜2 ，陈官芝1*

1 青岛大学附属医院皮肤科，山东 青岛

2 山东省郯城县皮肤病防治站，山东 临沂

收稿日期：2024年2月27日；录用日期：2024年3月21日；发布日期：2024年3月29日

摘 要

目的：点阵CO₂激光疗法在改善皮肤老化方面已经得到了广泛的应用，由于眶周皮肤的脆弱、易造成瘢痕的特性，目前针对眶周皮肤年轻化的激光治疗开展较少。本研究旨在确定点阵CO₂激光联合疗法在眶周皮肤再生表面修复中的有效性和安全性。方法：截至2023年12月01号，在3个主要数据库中进行了系统搜索。纳入的研究包括点阵CO₂激光或联合其他疗法来改善眼周老化的有效性及并发症，并报告了治疗的有效性和安全性；多篇文章报道同一组患者时，选择最近的报道完整数据的文章。排除标准包括体外研究、动物研究、未使用点阵CO2激光、专家述评、书信、会议摘要、数据不完整或不能获取、CO2点阵激光治疗但未声明关于眶周皱纹或年轻化的研究。结果：筛选后纳入7项临床试验，共纳入166例患者。研究汇总发现眶周皮肤老化及皱纹深度绝大部分都得到了改善，大多数患者都对这项技术感到满意。研究中发现患者在CO2激光术后耐受性良好，主要产生的并发症有包括红斑(n = 8)、色素沉着过度(n = 8)、渗出、渗血、局部水肿、结痂、疼痛、灼热、瘙痒、水疱等。随访时均再未观察到疱疹感染等其他不良反应。术后7天无瘢痕及表皮萎缩再形成。大多数并发症轻微且短暂。治疗后红斑发生率为0.10 (95% CI:0.03~0.18, p < 0.01)，色素沉着发生率为0.08 (95% CI: 0.03~0.16, p < 0.01)。结论：研究发现，点阵CO2激光治疗眶周皮肤年轻化是有效且安全的。由于缺乏高质量的报告，有必要进行更多的试验来证实这些结果。

关键词 年轻化，点阵CO₂ 激光，眶周，Meta分析

A Systematic Review and Meta-Analysis of Efficacy, Safety, and Satisfaction Rates of Fractional CO₂ Laser in Periocular Skin Rejuvenation

Yue Yuan1, Xiaohui Ji1, Jingxi Gu2, Guanzhi Chen1*

1 Dermatology Department, The Affiliated Hospital of Qingdao University, Qingdao Shandong

2 Skin Disease Prevention Station of Tancheng County, Shandong Province, Linyi Shandong Received: Feb. 27th, 2024; accepted: Mar. 21st , 2024; published: Mar. 29th, 2024

Abstract

Objective: Fractional CO₂ laser therapy has been widely used in improving skin aging. Due to the fragile and scarring properties of periorbital skin, laser therapy for periorbital skin rejuvenation is rarely carried out now. The aim of this study was to determine the efficacy and safety of fractional CO₂ laser combined therapy in periorbital skin regeneration surface repair. Methods: As of December 01, 2023, a systematic search was conducted in three major databases. Included studies included the efficacy and complications of fractional CO₂ laser or combined with other therapies to improve periocular aging, and reported the efficacy and safety of the treatment. When multiple articles report on the same group of patients, select the most recent article reporting completedata. Exclusion criteria included in vitro studies, animal studies, no use of a fractional CO₂ laser, expert reviews, letters, conference abstracts, incomplete or unavailable data, and studies on periorbital wrinkles or rejuvenation that did not claim fractional CO₂ laser treatment. Results: After screening, 7 clinical trials were included, involving a total of 166 patients. The study summary found that periorbital skin aging and wrinkle depth were largely improved, and most patients were satisfied with this treatment. The study found that patients were well tolerated after fractional CO₂ laser surgery, and the main complications included erythematosis (n = 8), hyper pigmentation (n = 8), exudation, bleeding, local edema, scab, pain, burning, pruritus, blisters, etc. No other adverse reactions such as herpes infection were observed during follow-up. No scar or epidermal atrophy was found 7 days after surgery. Most complications were mild and short-lived. The incidence of erythema after treatment was 0.10 (95% CI: 0.03~0.18, p < 0.01), and the incidence of hyper pigmentation was 0.08 (95% CI: 0.03~0.16, p < 0.01). Conclusion: It is found that fractional CO₂ laser is effective and safe in the treatment of periorbital skin rejuvenation. Due to paucity of high-quality reportings, additional trials are warranted to corroborate these results.

Keywords Rejuvenation, Fractional CO₂ Laser, Periorbital, Meta-Analysis

Copyright © 2024 by author(s) and Hans Publishers Inc.

This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).

http://creativecommons.org/licenses/by/4.0/

Hallmarks of aging: An expanding universe（2023）--3

Hallmarks of aging: An expanding universe（2023）--2

To be continued.

Hallmarks of aging: An expanding universe（2023）--1

Carlos Lo´ pez-Otı´n,1,2,3,* Maria A. Blasco,4 Linda Partridge,5,6 Manuel Serrano,7,8,9 and Guido Kroemer10,11,12,*

1 Departamento de Bioquı´mica y Biologı´a Molecular, Instituto Universitario de Oncologı´a (IUOPA), Universidad de Oviedo, Oviedo, Spain

2 Instituto de Investigacio´ n Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain

3 Centro de Investigacio´ n Biome´ dica en Red de Ca´ ncer (CIBERONC), Madrid, Spain

4 Telomeres and Telomerase Group, Molecular Oncology Program, Spanish National Cancer Centre (CNIO), Madrid, Spain

5 Department of Genetics, Evolution and Environment, Institute of Healthy Ageing, University College London, London, UK

6 Max Planck Institute for Biology of Ageing, Cologne, Germany

7 Institute for Research in Biomedicine (IRB Barcelona), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain

8 Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain

9 Altos Labs, Cambridge, UK

10 Centre de Recherche des Cordeliers, Equipe labellise´ e par la Ligue contre le cancer, Universite´ de Paris, Sorbonne Universite´ , INSERM U1138, Institut Universitaire de France, Paris, France

11 Metabolomics and Cell Biology Platforms, Gustave Roussy, Villejuif, France

12 Institut du Cancer Paris CARPEM, Department of Biology, Hoˆ pital Europe´ en Georges Pompidou, AP-HP, Paris, France

*Correspondence: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (C.L.-O.), 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。 (G.K.)

https://doi.org/10.1016/j.cell.2022.11.001

SUMMARY

Aging is driven by hallmarks fulfilling the following three premises: (1) their age-associated manifestation, (2) the acceleration of aging by experimentally accentuating them, and (3) the opportunity to decelerate, stop, or reverse aging by therapeutic interventions on them. We propose the following twelve hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis. These hallmarks are interconnected among each other, as well as to the recently proposed hallmarks of health, which include organizational features of spatial compartmentalization, maintenance of homeostasis, and adequate responses to strees.

Reprogramming to recover youthful epigenetic information and restore vision

Yuancheng Lu1, Benedikt Brommer2,3,11, Xiao Tian1,11, Anitha Krishnan3,4,11, Margarita Meer5,6,11, Chen Wang2,3, Daniel L. Vera1, Qiurui Zeng1, Doudou Yu1, Michael S. Bonkowski1, Jae-Hyun Yang1, Songlin Zhou2,3, Emma M. Hoffmann3,4, Margarete M. Karg3,4, Michael B. Schultz1, Alice E. Kane1, Noah Davidsohn7, Ekaterina Korobkina3,4, Karolina Chwalek1, Luis A. Rajman1, George M. Church7, Konrad Hochedlinger8, Vadim N. Gladyshev5, Steve Horvath9, Morgan E. Levine6, Meredith S. Gregory-Ksander3,4,* , Bruce R. Ksander3,4,* , Zhigang He2,3,* , David A. Sinclair1,10,*,#

1. Department of Genetics, Blavatnik Institute, Paul F. Glenn Center for Biology of Aging Research, Harvard Medical School, MA, USA;

2. Department of Neurology, Boston Children’s Hospital, Harvard Medical School, MA, USA;

3. Department of Ophthalmology, Harvard Medical School, Boston, MA, USA;

4. Schepens Eye Research Institute of Mass Eye & Ear, Harvard Medical School, MA, USA;

5. Division of Genetics, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, MA, USA;

6. Department of Pathology, Yale School of Medicine, New Haven, CT, USA;

7. Department of Genetics, Wyss Institute for Biologically Inspired Engineering, Harvard University, MA, USA;

8. Department of Molecular Biology, Cancer Center and Center for Regenerative Medicine, Massachusetts General Hospital, MA, USA;

9. Department of Human Genetics, David Geffen School of Medicine, University of California Los Angeles, CA, USA;

10. Laboratory for Aging Research, Department of Pharmacology, School of Medical Sciences, The University of New South Wales, Sydney, Australia;

11. These authors contributed equally: B. B., X. T., A. K., M. M.;

Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms

#* Correspondence: 该Email地址已收到反垃圾邮件插件保护。要显示它您需要在浏览器中启用JavaScript。.

Senior authors;

Contributions

Y.L. and D.A.S. conceived the project. Y.L., X.T., and D.A.S. wrote the manuscript with input from all co-authors. Y.L. was involved in all experiments and analyses. M.S.B. and J.-H.Y. provided early training to Y.L.. B.B., C.W., Q.Z., D.Y., S.Z., and Z.H. contributed to the optic nerve crush studies and imaging. A.K., D.Y., Q.Z., E.M.H., E.K., M.S.G.-K., and B.R.K. contributed to the glaucoma and ageing studies. M.M.K. and B.R.K. performed OCT imaging and analysis. M.M. and V.N.G. conducted ribosomal DNAm age analysis for mouse RGCs. M.E.L. developed DNAm ageing signature. D.L.V. performed the RNA-seq and gene association analysis. X.T. conducted human neuron experiments. S.H. conducted human methylation clock analysis. X.T., J.-H.Y., and K.H. helped with transgenic mouse fibroblasts work. M.S.B., X.T., M.B.S., A.E.K., L.A.R., helped with systemic AAV9 experiments. N.D., and G.M.C. helped with plasmid constructs and AAV9 production. K.C. helped with grant applications and project management. M.S.G.-K., B.R.K., Z.H., and D.A.S. jointly supervised this work.

Conflict of interest

D.A.S. is a consultant to, inventor of patents licensed to, board member of and equity owner of Iduna Therapeutics, a Life Biosciences company developing epigenetic reprograming therapies. D.A.S. is an advisor to Zymo Research, an epigenetics tools company. Additional disclosures are at https://genetics.med.harvard.edu/sinclair/people/sinclair-other.php. Y.L., L.A.R. and S.H. are equity owners of Iduna Therapeutics, a Life Biosciences company. D.L.V. is an advisor to Liberty Biosecurity. M.S.B. is a shareholder in MetroBiotech. K.C. is an equity owner in Life Biosciences and affiliates. N.D. and G.M.C. are co-founders of Rejuvenate Bio. Disclosures for G.M.C. can be found at http://arep.med.harvard.edu/gmc/tech.html. M.E.L. is a bioinformatics advisor to Elysium Health. Y.L., N.D. and D.A.S. are inventors on patents arising from this work (WO/2020/069373 and WO/2020/069339), filed by the President and Fellows of Harvard College. The other authors declare no competing interests.